Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
featured
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

lung cancer
crizotinib
lung carcinoma
  • 98 views
  • 23 Nov, 2020
  • 1 location
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer

The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional

metastasis
folfox regimen
kidney function tests
adenocarcinoma
lipase
  • 10 views
  • 08 Nov, 2020
  • 1 location
5FU/LV Irinotecan Temozolomide and Bevacizumab for MGMT Silenced Microsatellite Stable Metastatic Colorectal Cancer.

An upfront-intensified treatment combining all the three active cytotoxic agents in metastatic colorectal cancer (mCRC) including fluoropyrimidines, oxaliplatin, irinotecan (FOLFOXIRI) plus

  • 1 views
  • 01 Mar, 2021
  • 1 location
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

cytotoxic agents results in additive anti-tumor activity (10), initiating justification for combination studies. A recent trial, however, reported an unexpected incidence of cardiac toxicity

soft tissue sarcoma
advanced soft tissue sarcoma
gemcitabine
immunomodulators
ifosfamide
  • 13 views
  • 07 Nov, 2020
  • 1 location
The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer

Purpose: to demonstrate a 10% recurrence risk reduction for patients treated with Hypersal versus normal saline immediately following TURBT. Design: prospective randomized double-blind placebo controlled trial. Outline: eligible patients with non-muscle invasive bladder cancer who undergo TURBT at our center will be randomized to receive either 40ml of normal saline …

  • 0 views
  • 26 Feb, 2021
  • 1 location
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Treatment with polysorbate 80-solved Docetaxel (Taxotere) is hampered by the requirement to co-administer steroids. Chronic (intermittent) steroids are negatively impacting bone health and have well known immunosuppressive effects. Despite steroid premedication, polysorbate 80-solved Docetaxel (Taxotere) results in occasional infusion reactions due to the solvent polysorbate 80. Docetaxel micellar is a …

  • 0 views
  • 15 Jun, 2021
  • 3 locations
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Background Metastatic urothelial carcinoma is lethal and has no cure. Response rates to current treatments are modest. Researchers want to find new strategies to treat the disease. In this study, they will test a drug called M7824. The drug is a new immunotherapy that blocks the pathways that cancer cells …

transitional cell carcinoma
carcinoma
progressive disease
metastatic urothelial carcinoma
carboplatin
  • 0 views
  • 23 Jul, 2021
  • 1 location
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 24 Jan, 2021
  • 2 locations
  • 0 views
  • 26 Jan, 2021
  • 32 locations
International Study for Treatment of High Risk Childhood Relapsed ALL 2010

The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.

  • 9 views
  • 25 Jan, 2021
  • 19 locations